The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/45217
• EU PAS number:
  EUPAS41519
• Study ID:
  45217
• Official title and acronym:
  The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients
• DARWIN EU® study:
  No
• Study countries:
  Greece

  Netherlands

  Portugal

  Spain

  Sweden

  Ukraine

  United Kingdom
• Study description:
  A study to determine the prevalence of comorbid conditions in COPD patients, and to assess their association on health status and COPD symtoms in primary care patients, using eight databases from UK, Greece, Portugal, Spain, Sweden, Ukraine, and the Netherlands, comprising 91,000 primary care COPD patients.
• Study status:
  Ongoing

Research institutions and networks

Institutions

International Primary Care Respiratory Group (IPCRG)

United Kingdom

University of Birmingham

Balearic Islands Public Health System (IBSalut)

Spain

Dept. Of Public Health and Caring Sciences, Family Medicine, Uppsala University Uppsala, Sweden, Department of Family Medicine at Kharkov Medical Academy Kharkov, Ukraine, Institute of Applied Health Research, University of Birmingham Birmingham, UK, Department of Social Medicine, Faculty of Medicine, University of Crete Crete, Greece, Mallorca Research Institute IdisPa, IBSalut Palma, Spain, Stichting Zorgdraad Foundation Oosterbeek, The Netherlands, Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen Aberdeen, UK, Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, and ICVS/3B's-PT Government Associate Laboratory Braga/Guimarães, Portugal

Networks

Respiratory Effectiveness Group (REG)

Belgium

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Spain

Sweden

United Kingdom

Optimum Patient Care (OPC) Network

United Kingdom (Northern Ireland)

Study timelines

Date when funding contract was signed

Actual: 13/10/2015

Study start date

Actual: 17/11/2016

Date of final study report

Planned: 31/12/2022

Sources of funding

Non-for-profit organisation (e.g. charity)

More details on funding

IPCRG

Study protocol

Initial protocol

Ställberg B et al. Prevalence of Comorbidity in COPD A protocol. NPJ PCRM 2016 (1)

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable